Morning Briefing
Summaries of health policy coverage from major news organizations
EU Could Approve New Shots For Omicron In Months
Reuters: EU Could Approve Shot Against New Coronavirus Variant In 3-4 Months
The EU drug regulator said on Tuesday it could approve vaccines adapted to target the Omicron variant of the coronavirus within three to four months if needed, but that existing shots would continue to provide protection. Speaking to the European Parliament, European Medicines Agency (EMA) executive director Emer Cooke said it was not known if drugmakers would need to tweak their vaccines to protect against Omicron, but the EMA was preparing for that possibility. (Burger and Aripaka, 11/30)
AP: Mexico To Reverse Course, Give COVID-19 Booster Shots
Mexican officials have reversed their previous position against giving coronavirus booster shots and said Tuesday they are studying a plan to administer third doses to people over 60. The announcement came as Mexico nears 450,000 deaths from COVID-19. The country has fully vaccinated only about 50% of its 126 million people. President Andrés Manuel López Obrador said plans for the boosters are still being drawn up, but added, “It won’t be long, we have the vaccines.” (11/30)
Bloomberg: Israel Should Weigh Mandatory Vaccination, Health Official Says
Israel’s coronavirus czar said the country should begin considering mandatory vaccination now that the new omicron variant has emerged. “Mandatory vaccination needs to be considered, whether through legislation or otherwise, especially given the fact that not only is the pandemic here, but I fear it will get worse,” Salman Zarka said on 103FM radio. He said he changed his mind following the appearance of the new variant, which has been identified in several Israelis. (Ackerman, 12/1)
The New York Times: South African Company Nears License To Sell J. & J. Covid Shot Across Africa
The South African drug maker Aspen Pharmacare announced on Tuesday that it was finalizing the first agreement to control production of a Covid-19 vaccine in Africa. The deal, with Johnson & Johnson, would allow Aspen to bottle and market the Johnson & Johnson vaccine across Africa under the brand name Aspenovax. Aspen would then have the right to determine to whom the vaccine will be sold, in what quantities and at what price. (Nolen, 11/30)
